These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 36360192)
1. Comprehensive Clinical and Genetic Analysis of Kirchner K; Gamulin M; Kulis T; Sievers B; Kastelan Z; Lessel D Genes (Basel); 2022 Oct; 13(11):. PubMed ID: 36360192 [TBL] [Abstract][Full Text] [Related]
2. Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors. AlDubayan SH; Pyle LC; Gamulin M; Kulis T; Moore ND; Taylor-Weiner A; Hamid AA; Reardon B; Wubbenhorst B; Godse R; Vaughn DJ; Jacobs LA; Meien S; Grgic M; Kastelan Z; Markt SC; Damrauer SM; Rader DJ; Kember RL; Loud JT; Kanetsky PA; Greene MH; Sweeney CJ; Kubisch C; Nathanson KL; Van Allen EM; Stewart DR; Lessel D; JAMA Oncol; 2019 Apr; 5(4):514-522. PubMed ID: 30676620 [TBL] [Abstract][Full Text] [Related]
3. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. Kote-Jarai Z; Mikropoulos C; Leongamornlert DA; Dadaev T; Tymrakiewicz M; Saunders EJ; Jones M; Jugurnauth-Little S; Govindasami K; Guy M; Hamdy FC; Donovan JL; Neal DE; Lane JA; Dearnaley D; Wilkinson RA; Sawyer EJ; Morgan A; Antoniou AC; Eeles RA; Ann Oncol; 2015 Apr; 26(4):756-761. PubMed ID: 25595936 [TBL] [Abstract][Full Text] [Related]
4. Rare germline genetic variants and risk of aggressive prostate cancer. Nguyen-Dumont T; MacInnis RJ; Steen JA; Theys D; Tsimiklis H; Hammet F; Mahmoodi M; Pope BJ; Park DJ; Mahmood K; Severi G; Bolton D; Milne RL; Giles GG; Southey MC Int J Cancer; 2020 Oct; 147(8):2142-2149. PubMed ID: 32338768 [TBL] [Abstract][Full Text] [Related]
5. A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer. Wu Y; Yu H; Zheng SL; Na R; Mamawala M; Landis T; Wiley K; Petkewicz J; Shah S; Shi Z; Novakovic K; McGuire M; Brendler CB; Ding Q; Helfand BT; Carter HB; Cooney KA; Isaacs WB; Xu J Prostate; 2018 Jun; 78(8):607-615. PubMed ID: 29520813 [TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. Tischkowitz MD; Yilmaz A; Chen LQ; Karyadi DM; Novak D; Kirchhoff T; Hamel N; Tavtigian SV; Kolb S; Bismar TA; Aloyz R; Nelson PS; Hood L; Narod SA; White KA; Ostrander EA; Isaacs WB; Offit K; Cooney KA; Stanford JL; Foulkes WD Cancer Lett; 2008 Oct; 270(1):173-80. PubMed ID: 18571837 [TBL] [Abstract][Full Text] [Related]
7. Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations. Maier C; Herkommer K; Luedeke M; Rinckleb A; Schrader M; Vogel W Prostate; 2014 Oct; 74(14):1444-51. PubMed ID: 25111659 [TBL] [Abstract][Full Text] [Related]
8. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cybulski C; Huzarski T; Górski B; Masojć B; Mierzejewski M; Debniak T; Gliniewicz B; Matyjasik J; Złowocka E; Kurzawski G; Sikorski A; Posmyk M; Szwiec M; Czajka R; Narod SA; Lubiński J Cancer Res; 2004 Apr; 64(8):2677-9. PubMed ID: 15087378 [TBL] [Abstract][Full Text] [Related]
10. A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients. Wendt C; Muranen TA; Mielikäinen L; Thutkawkorapin J; Blomqvist C; Jiao X; Ehrencrona H; Tham E; Arver B; Melin B; Kuchinskaya E; Stenmark Askmalm M; Paulsson-Karlsson Y; Einbeigi Z; von Wachenfeldt Väppling A; Kalso E; Tasmuth T; Kallioniemi A; Aittomäki K; Nevanlinna H; Borg Å; Lindblom A Sci Rep; 2021 Jul; 11(1):14763. PubMed ID: 34285278 [TBL] [Abstract][Full Text] [Related]
11. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance. Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080 [TBL] [Abstract][Full Text] [Related]
12. Inherited DNA Repair Gene Mutations in Men with Lethal Prostate Cancer. Rantapero T; Wahlfors T; Kähler A; Hultman C; Lindberg J; Tammela TL; Nykter M; Schleutker J; Wiklund F Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32183364 [TBL] [Abstract][Full Text] [Related]
13. CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden. Wagenius M; Borg A; Johansson L; Giwercman A; Bratt O Scand J Urol Nephrol; 2006; 40(1):23-5. PubMed ID: 16452051 [TBL] [Abstract][Full Text] [Related]
14. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067 [TBL] [Abstract][Full Text] [Related]
15. Small fraction of testicular cancer cases may be causatively related to CHEK2 inactivating germ-line mutations: evidence for somatic loss of the remaining CHEK2 allele in the tumor tissue. Ni VI; Ivantsov AO; Kotkova MA; Baskina SV; Ponomareva EV; Orlova RV; Topuzov EE; Kryukov KK; Shelekhova KV; Aleksakhina SN; Sokolenko AP; Imyanitov EN Fam Cancer; 2021 Jan; 20(1):49-53. PubMed ID: 32451744 [TBL] [Abstract][Full Text] [Related]
16. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Kilpivaara O; Bartkova J; Eerola H; Syrjäkoski K; Vahteristo P; Lukas J; Blomqvist C; Holli K; Heikkilä P; Sauter G; Kallioniemi OP; Bartek J; Nevanlinna H Int J Cancer; 2005 Feb; 113(4):575-80. PubMed ID: 15472904 [TBL] [Abstract][Full Text] [Related]
18. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study. Näslund-Koch C; Nordestgaard BG; Bojesen SE J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562 [TBL] [Abstract][Full Text] [Related]
19. The Prevalence of CHEK1 and CHEK2 Mutations in Prostate Cancer: a Retrospective Cohort Study. Alorjani M; Aburub M; Al-Trad B; Hamad MA; AbuAlarja M; Bashir SA; Al-Batayneh K; Zoubi MA Med Arch; 2023 Feb; 77(1):8-12. PubMed ID: 36919124 [TBL] [Abstract][Full Text] [Related]
20. Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline Thibodeau ML; Reisle C; Zhao E; Martin LA; Alwelaie Y; Mungall KL; Ch'ng C; Thomas R; Ng T; Yip S; J Lim H; Sun S; Young SS; Karsan A; Zhao Y; Mungall AJ; Moore RA; J Renouf D; Gelmon K; Ma YP; Hayes M; Laskin J; Marra MA; Schrader KA; Jones SJM Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28514723 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]